Known targets — ChEMBL curated mechanism
ABL1ACEACHEACVR1ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3AGTR1ALKAVPR1AAVPR2BCHEBCRCA2CACNA1ACACNA1BCACNA1CCACNA1DCACNA1ECACNA1FCACNA1GCACNA1HCACNA1ICACNA1SCACNA2D1CACNA2D2CACNA2D3CACNA2D4CACNB1CACNB2CACNB3CACNB4CACNG1CACNG2CACNG3CACNG4CACNG5CACNG6CACNG7CACNG8CALCRLCASRCCR5CDK4CDK6CFBCHRM1CHRM2CHRM3CHRM4CHRM5CHRNA1CHRNA3CHRNA7CHRNB1CHRNB4CHRNDCHRNECHRNGCOXFA4COXFA4L2CRBNCSF1RCUL4ACYP19A1DDB1DPP4DRD1DRD2DRD3DRD4EDNRAEGFREML4ERBB2ERBB4ESR1ESR2FGFR1FGFR3FLT1FLT3FLT4GAAGABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQGHSRGLAGNRHRGPD2GRIN1GRIN2AGRIN2BGRIN2CGRIN2DGRIN3AGRIN3BGSTP1HCN4HCRTR1HCRTR2HDAC1HDAC10HDAC11HDAC2HDAC3HDAC4HDAC5HDAC6HDAC7HDAC8HDAC9HRH1HRH2HRH3HSD11B1HSP90AA1HSP90AB1HTR1AHTR1BHTR1DHTR1EHTR1FHTR2AHTR2BHTR2CHTR3AHTR3BHTR3CHTR3DHTR3EHTR4HTR5AHTR6HTR7IMPDH1IMPDH2ITGA2BITGB3ITKJAK1JAK2KCNA1KCNA10KCNA2KCNA3KCNA4KCNA5KCNA6KCNA7KCNB1KCNB2KCNC1KCNC2KCNC3KCNC4KCND1KCND2KCND3KCNF1KCNG1KCNG2KCNG3KCNG4KCNH1KCNH2KCNH3KCNH4KCNH5KCNH6KCNH7KCNH8KCNJ2KCNJ3KCNJ5KCNK3KCNK9KCNQ1KCNQ2KCNQ3KCNQ4KCNQ5KCNS1KCNS2KCNS3KCNV1KCNV2KDRKITKLKB1LCKMMAOAMAOBMAPK14METMMP1MMP13MMP7MMP8MT-ND1MT-ND2MT-ND3MT-ND4MT-ND4LMT-ND5MT-ND6NDUFA1NDUFA10NDUFA11NDUFA12NDUFA13NDUFA2NDUFA3NDUFA5NDUFA6NDUFA7NDUFA8NDUFA9NDUFAB1NDUFAF1NDUFAF2NDUFAF3NDUFAF4NDUFB1NDUFB10NDUFB11NDUFB2NDUFB3NDUFB4NDUFB5NDUFB6NDUFB7NDUFB8NDUFB9NDUFC1NDUFC2NDUFS1NDUFS2NDUFS3NDUFS4NDUFS5NDUFS6NDUFS7NDUFS8NDUFV1NDUFV2NDUFV3NR3C1NS5ANTRK1NTRK2NTRK3ODC1OPRD1OPRK1OPRM1P2RY12PAHPARP1PDE3APDE3BPDE4APDE4BPDE4CPDE4DPDE5APDE7APDE7BPDE8APDE8BPDGFRAPDGFRBPIK3CAPIK3CDPNPPOLA1POLA2POLD1POLD2POLD3POLD4POLEPOLE2POLE3PPARGPRIM1PRIM2PRKCAPRKCBPRKCDPRKCEPRKCGPRKCHPRKCIPRKCQPRKCZPRKD1PRKD3PTGS1PTGS2RBX1RENRETROCK1ROCK2RPE65RRM1RRM2RRM2BS1PR1S1PR2S1PR3S1PR4S1PR5SCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASCNN1ASCNN1BSCNN1GSIGMAR1SLC18A2SLC6A1SLC6A2SLC6A3SLC6A4SLC9A3SRCTACR1TOP1TOP2ATOP2BTTRTYMPdacAdacBdacCembAfolAftsIgyrAgyrBmrcAmrcBmrdAparCparEpolrplArplBrplCrplDrplErplFrplIrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmE2rpmFrpmGrpmG1rpmG2rpmG3rpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Amosulalol. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADRB2 known ✓ | P07550 | 13/20 | 0.98 |
| ▸ | DRD2 known ✓ | P14416 | 6/20 | 0.98 |
| ▸ | DRD3 known ✓ | P35462 | 6/20 | 0.98 |
| ▸ | ADRB1 known ✓ | P08588 | 6/20 | 0.98 |
| ▸ | ADRA1A known ✓ | P35348 | 6/20 | 0.98 |
| ▸ | HTR1A known ✓ | P08908 | 4/20 | 0.98 |
| ▸ | ADRA2A known ✓ | P08913 | 2/20 | 0.98 |
| ▸ | ADRA2B known ✓ | P18089 | 2/20 | 0.98 |
| ▸ | ADRA2C known ✓ | P18825 | 2/20 | 0.98 |
| ▸ | HTR2A known ✓ | P28223 | 2/20 | 0.98 |
| ▸ | HTR2B known ✓ | P41595 | 2/20 | 0.98 |
| ▸ | KCNH2 known ✓ | Q12809 | 2/20 | 0.98 |
| ▸ | SLC6A4 known ✓ | P31645 | 1/20 | 0.98 |
| ▸ | HRH1 known ✓ | P35367 | 1/20 | 0.98 |
| ▸ | PDE4D known ✓ | Q08499 | 1/20 | 0.98 |
| ▸ | DRD1 known ✓ | P21728 | 4/20 | 0.66 |
| ▸ | DRD4 known ✓ | P21917 | 4/20 | 0.66 |
| ▸ | ADRA1D known ✓ | P25100 | 5/20 | 0.44 |
| ▸ | ADRA1B known ✓ | P35368 | 5/20 | 0.44 |
| ▸ | ADRB3 known ✓ | P13945 | 2/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Amosulalol SCHEMBL30136493 | 0.99 | ADRB2 (1.00) | ADRB2DRD2DRD3ADRB1ADRA1A | |
| Amosulalol SCHEMBL6509394 | 0.99 | ADRB2 (1.00) | ADRB2DRD2DRD3ADRB1ADRA1A | |
| Amosulalol SCHEMBL48933 | 0.99 | ADRB2 (1.00) | ADRB2DRD2DRD3ADRB1ADRA1A | |
| Amosulalol SCHEMBL11020103 | 0.98 | ADRB2 (0.98) | ADRB2DRD2DRD3ADRB1ADRA1A | |
| Amosulalol SCHEMBL1650308 | 0.97 | ADRB2 (0.96) | ADRB2DRD2DRD3ADRB1ADRA1A | |
| Hydrochloric Acid SCHEMBL11472523 | 0.92 | ADRB2 (0.83) | ADRB2DRD2DRD3ADRB1ADRA1A | |
| Hydrochloric Acid SCHEMBL11400227 | 0.92 | ADRB2 (0.83) | ADRB2DRD2DRD3ADRB1ADRA1A | |
| Hydrochloric Acid SCHEMBL11472525 | 0.91 | ADRB2 (0.81) | ADRB2DRD2DRD3ADRB1ADRA1A | |
| SCHEMBL11473050 | 0.91 | ADRB2 (0.85) | ADRB2DRD2DRD3ADRB1ADRA1A | |
| SCHEMBL11471245 | 0.91 | ADRB2 (0.85) | ADRB2DRD2DRD3ADRB1ADRA1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 486 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-108066305-A | Improve the method for oral disintegrating tablet hardness and disintegration and positioning release oral disnitegration tablet | 深圳万和制药有限公司 | 2018-05-25 | — | — | CN | claimed |
| CN-102050766-B | Synthesis method for amosulalol hydrochloride | ANHUI NEW STAR PHARMACEUTICAL DEV CO LTD | 2013-08-07 | — | — | CN | claimed |
| CN-102050766-A | Synthesis method for amosulalol hydrochloride | ANHUI NEW STAR PHARMACEUTICAL DEV CO LTD | 2011-05-11 | — | — | CN | claimed |
| US-7807701-B2 | Dibenzylamine compounds and pharmaceutical use thereof | JAPAN TOBACCO INC. (JP) | 2010-10-05 | — | — | US | claimed |
| CN-101838218-A | Ester compound and pharmaceutical use of the same | JAPAN TOBACCO INC | 2010-09-22 | — | — | CN | claimed |
| US-20100158996-A1 | ESTER COMPOUND AND MEDICAL USE THEREOF | JAPAN TOBACCO INC. | 2010-06-24 | — | — | US | claimed |
| US-7625948-B2 | Ester compound and medicinal use thereof | JAPAN TOBACCO INC. (JP) | 2009-12-01 | — | — | US | claimed |
| CN-101208306-A | Pyrazole compounds and diabetes therapeutic agent containing the same | JAPAN TOBACCO INC (JP) | 2008-06-25 | — | — | CN | claimed |
| US-20080146620-A1 | Dibenzylamine Compounds and Pharmaceutical Use Thereof | JAPAN TOBACCO INC. (JP) | 2008-06-19 | — | — | US | claimed |
| US-7332514-B2 | Dibenzylamine compound and medicinal use thereof | JAPAN TOBACCO INC. (JP) | 2008-02-19 | — | — | US | claimed |
| US-5811547-A | Method for inducing crystalline state transition in medicinal substance | NIPPON SHINYAJU CO., LTD. (JP) | 1998-09-22 | — | — | US | claimed |
| US-5258186-A | Drug release controlling coating material for long acting formulations | YAMANOUCHI PHARMACEUTICAL CO., LTD. (JP) | 1993-11-02 | — | — | US | claimed |
| US-5001113-A | Di- or tripeptide renin inhibitors containing lactam conformational restriction in ACHPA | MERCK & CO., INC. (US) | 1991-03-19 | — | — | US | claimed |
| EP-0136103-B1 | AMOSULALOL HYDROCHLORIDE LONG ACTING FORMULATIONS | YAMANOUCHI PHARMACEUTICAL CO. LTD. (JP) | 1990-10-31 | — | — | EP | claimed |
| EP-0386967-A2 | A drug-release controlling coating material for long acting formulations | YAMANOUCHI PHARMACEUTICAL CO. LTD. (JP) | 1990-09-12 | — | — | EP | claimed |
| US-4782043-A | HYPOTENSIVES | MERCK & CO., INC. (US) | 1988-11-01 | — | — | US | claimed |
| US-4765988-A | Amosulalol hydrochloride long acting formulations | YAMANOUCHI PHARMACEUTICAL CO., LTD. (JP) | 1988-08-23 | — | — | US | claimed |
| US-4724148-A | Amosulalol hydrochloride long acting formulation | YAMANOUCHI PHARMACEUTICAL CO., LTD. (JP) | 1988-02-09 | — | — | US | claimed |
| EP-0156318-A2 | C-terminal amide cyclic renin inhibitors containing peptide isosteres | MERCK & CO. INC. (US) | 1985-10-02 | — | — | EP | claimed |
| EP-0136103-A2 | Amosulalol hydrochloride long acting formulations | YAMANOUCHI PHARMACEUTICAL CO. LTD. (JP) | 1985-04-03 | — | — | EP | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080146620-A1 | Dibenzylamine Compounds and Pharmaceutical Use Thereof | CETP, PCSK9, CES1 | ADRB2 430/4885DRD2 365/4885DRD3 437/4885 |
| US-20100158996-A1 | ESTER COMPOUND AND MEDICAL USE THEREOF | LIPC, CES1, MTTP | ADRB2 1447/4885DRD2 3079/4885DRD3 2686/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.